Omthera Pharmaceuticals

The company's business model was centered on the clinical development of its lead product candidate, Epanova. Omthera's strategy involved navigating the drug through extensive clinical trials to secure regulatory approval and eventually commercialize it for patients with severe hypertriglyceridemia. The company's primary asset, Epanova, is a prescription omega-3 free fatty acid composition derived from fish oils, designed to lower high triglyceride levels. A key feature of Epanova was its formulation as a coated soft gelatin capsule containing a mixture of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which could be taken once daily, with or without food, enhancing patient convenience. The product's worldwide rights were held under a license from Chrysalis Pharma AG.

Omthera successfully advanced Epanova through Phase III trials, reporting positive results in 2012 from the EVOLVE and ESPRIT studies, which demonstrated its effectiveness in reducing triglyceride levels. Following a brief period as a publicly traded company on NASDAQ starting in April 2013, Omthera was acquired by AstraZeneca in July 2013. The acquisition was valued at approximately $323 million, with an additional $120 million in contingent value rights tied to milestones, bringing the total potential value to $443 million. Epanova received FDA approval in May 2014 as an adjunct to diet for reducing triglyceride levels in adults with severe hypertriglyceridemia. However, in 2020, AstraZeneca announced the discontinuation of a large-scale cardiovascular outcomes trial (STRENGTH) for Epanova, as it was unlikely to show a benefit in reducing cardiovascular risk in patients with mixed dyslipidemia. Keywords: Omthera Pharmaceuticals, Epanova, dyslipidemia, hypertriglyceridemia, AstraZeneca acquisition, cardiovascular disease, omega-3 fatty acids, lipid disorders, Gerald L. Wisler, Michael H. Davidson, clinical trials, EVOLVE trial, ESPRIT trial, STRENGTH trial, Chrysalis Pharma AG, triglyceride reduction, prescription therapeutics, pharmaceutical development, lipid-lowering therapy, specialty pharmaceuticals, cardiovascular risk